Literature DB >> 26840943

IGF/STAT3/NANOG/Slug Signaling Axis Simultaneously Controls Epithelial-Mesenchymal Transition and Stemness Maintenance in Colorectal Cancer.

Chao Yao1, Li Su1, Juanjuan Shan1, Chuanlin Zhu1, Limei Liu1, Chungang Liu1, Yanmin Xu1, Zhi Yang1, Xiuwu Bian1, Jimin Shao2, Jianming Li3, Maode Lai2, Junjie Shen1, Cheng Qian1.   

Abstract

Discovery of epithelial-mesenchymal transition (EMT) and cancer stem cells (CSCs) are two milestones in people exploring the nature of malignant tumor in recent decades. Although some studies have presented the potential connections between them, the link details, underneath their superficial correlation, are largely unknown. In this study, we identified a small subpopulation of NANOG-positive colorectal cancer (CRC) cells, and demonstrated that they exhibited characteristics of CSCs and EMT traits simultaneously. Furthermore, we found that NANOG was a core factor in regulating both of EMT and stemness in CRC cells, NANOG modulate EMT and metastasis by binding to Slug promoter and transcriptionally regulate Slug expression. For the first time, we demonstrated that NANOG was regulated by extracellular IGF signaling pathway via STAT3 phosphorylation in CRC. This coincides with that IGF receptor IGF-1R is often increasing expressed in malignant metastasis colon cancer. Taken together, our data define the crucial functions of IGF/STAT3/NANOG/Slug signaling axis in the progression of CRC by operating EMT and CSCs properties, which make them served as potential therapeutic targets for treatment of CRC.
© 2016 AlphaMed Press.

Entities:  

Keywords:  Cancer stem cells; EMT; Insulin-like growth factors; Self-renewal; Signal transduction; Stem cell-microenvironment interactions

Mesh:

Substances:

Year:  2016        PMID: 26840943     DOI: 10.1002/stem.2320

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  47 in total

1.  Meeting report: Metastasis Research Society-Chinese Tumor Metastasis Society joint conference on metastasis.

Authors:  Katherine Bankaitis; Lucia Borriello; Thomas Cox; Conor Lynch; Andries Zijlstra; Barbara Fingleton; Miodrag Gužvić; Robin Anderson; Josh Neman
Journal:  Clin Exp Metastasis       Date:  2017-03-04       Impact factor: 5.150

Review 2.  Systematic review of the old and new concepts in the epithelial-mesenchymal transition of colorectal cancer.

Authors:  Simona Gurzu; Camelia Silveanu; Annamaria Fetyko; Vlad Butiurca; Zsolt Kovacs; Ioan Jung
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

3.  STAT3 mediates RCP-induced cancer cell invasion through the NF-κB/Slug/MT1-MMP signaling cascade.

Authors:  Su Jin Cho; Bo Young Jeong; Young Soo Song; Chang Gyo Park; Do Yeun Cho; Hoi Young Lee
Journal:  Arch Pharm Res       Date:  2022-07-09       Impact factor: 6.010

4.  Depletion of Fibroblast Growth Factor 12 Restrains the Viability, Stemness, and Motility of Colorectal Cancer.

Authors:  Xueyuan Gao; Zuowei Liao; Rukui Su; Dongni Zheng; Guoyuan Huang; Zhong Huang; Xueyuan Cheng
Journal:  Biomed Res Int       Date:  2022-07-11       Impact factor: 3.246

5.  Sterol regulatory element-binding protein 1 cooperates with c-Myc to promote epithelial-mesenchymal transition in colorectal cancer.

Authors:  Duanyang Zhai; Chunhui Cui; Lang Xie; Lianxu Cai; Jinlong Yu
Journal:  Oncol Lett       Date:  2018-02-15       Impact factor: 2.967

Review 6.  Insulin Receptor Isoforms in Physiology and Disease: An Updated View.

Authors:  Antonino Belfiore; Roberta Malaguarnera; Veronica Vella; Michael C Lawrence; Laura Sciacca; Francesco Frasca; Andrea Morrione; Riccardo Vigneri
Journal:  Endocr Rev       Date:  2017-10-01       Impact factor: 19.871

7.  Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas.

Authors:  Tony Navas; Robert J Kinders; Scott M Lawrence; Katherine V Ferry-Galow; Suzanne Borgel; Melinda G Hollingshead; Apurva K Srivastava; Sergio Y Alcoser; Hala R Makhlouf; Rodrigo Chuaqui; Deborah F Wilsker; Mariam M Konaté; Sarah B Miller; Andrea Regier Voth; Li Chen; Tomas Vilimas; Jyothi Subramanian; Lawrence Rubinstein; Shivaani Kummar; Alice P Chen; Donald P Bottaro; James H Doroshow; Ralph E Parchment
Journal:  Cancer Res       Date:  2019-11-15       Impact factor: 12.701

Review 8.  The shifting paradigm of colorectal cancer treatment: a look into emerging cancer stem cell-directed therapeutics to lead the charge toward complete remission.

Authors:  Jessica Kopenhaver; Madison Crutcher; Scott A Waldman; Adam E Snook
Journal:  Expert Opin Biol Ther       Date:  2021-05-24       Impact factor: 5.589

9.  Cryptolepine inhibits hepatocellular carcinoma growth through inhibiting interleukin-6/STAT3 signalling.

Authors:  Seth A Domfeh; Patrick W Narkwa; Osbourne Quaye; Kwadwo A Kusi; Gordon A Awandare; Charles Ansah; Alimatu Salam; Mohamed Mutocheluh
Journal:  BMC Complement Med Ther       Date:  2021-06-02

Review 10.  Lessons to Learn for Adequate Targeted Therapy Development in Metastatic Colorectal Cancer Patients.

Authors:  Helena Oliveres; David Pesántez; Joan Maurel
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.